INOVIO enters $60M at-the-market equity distribution agreement with Oppenheimer

INOVIO PHARMACEUTICALS, INC.

Sales agreement enables INOVIO to sell up to $60M of common stock via Oppenheimer as agent.
Commission of up to 3% of gross proceeds; INOVIO may suspend or terminate offering at any time.
Shares sold under existing S-3 registration statement; proceeds for general corporate purposes.
No obligation to sell any shares; sales are at INOVIO's sole discretion and subject to market conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.